Table 5.

Effect of treatment on change from baseline in ADHD-RS-IV total score (drug—placebo)

Drug	Mean change	95% credible interval	Probability of the treatment being most effective among all	Probability of GXR being more effective compared with each treatment
GXR	−8.68	(−10.63, −6.72)	<1%	–
LDX	−14.98	(−17.14, −12.80)	99.96%	<1%
ATX	−6.88	(−8.22, −5.49)	<1%	93.91%
MPH-ER	−9.33	(−11.63, −7.04)	<1%	33.04%

Core Bayesian analysis: random-effects model, combined doses, excluding short-term studies, and adjusted for age and percent female

Both forced- and optimal-dose studies were included in the network. Among forced-dose studies, randomization arms included GXR 1, 2, 3, and 4 mg/day; LDX 30, 50, and 70 mg/day; and ATX 0.5, 1.2, and 1.8 mg/kg/day. All MPH-ER studies were optimal-dose studies. MPH-IR was not included in the network because there were no available trials

ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder Rating Scale Version IV, ATX atomoxetine, GXR guanfacine extended release, LDX lisdexamfetamine dimesylate, MPH-ER methylphenidate extended release, MPH-IR methylphenidate immediate release